The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction

African Journal of Traditional, Complementary and Alternative Medicines

Volumn 11, Issue 4, 2014, Pages 54-61

  Fasinu, Pius S ^a,b   Bouic, Patrick J ^a,c   Rosenkranz, Bernd ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Stellenbosch University Synexa Life Sciences   (South Africa)

Author keywords

Cytochrome P450; Drug metabolism; Enzyme inhibition; Herb drug interaction; Liver microsomes

Indexed keywords

BOWIEA VOLUBILIS EXTRACT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; MEPHENYTOIN; PHENACETIN; PLANT EXTRACT; SPIROSTACHYS AFRICANA EXTRACT; TESTOSTERONE; TULBAGHIA VIOLACEA EXTRACT; UNCLASSIFIED DRUG; CYTOCHROME P450 3A; DRUG;

ARTICLE; BARK; BOWIEA VOLUBILIS; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; HYDROXYLATION; IC50; LIVER MICROSOME; MEDICINAL PLANT; NONHUMAN; PLANT BULB; PLANT STEM; SPIROSTACHYS AFRICANA; TULBAGHIA VIOLACEA; ANGIOSPERM; DRUG EFFECTS; EUPHORBIACEAE; LILIACEAE; METABOLISM; SOUTH AFRICA;

ANGIOSPERMS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; DICLOFENAC; EUPHORBIACEAE; HERB-DRUG INTERACTIONS; HUMANS; HYDROXYLATION; LILIACEAE; MEPHENYTOIN; MICROSOMES, LIVER; PHARMACEUTICAL PREPARATIONS; PHENACETIN; PLANT EXTRACTS; PLANTS, MEDICINAL; SOUTH AFRICA; TESTOSTERONE;

EID: 84924743757     PISSN: 01896016     EISSN: 01896016     Source Type: Journal    
DOI: 10.4314/ajtcam.v11i4.9     Document Type: Article

References (51)

1. Beach, R.A., Gantsho, N., Flesche, J., Scott, C. and Khumalo, N.P. (2010). Possible drug reaction, eosinophilia and systemic symptoms (DRESS) syndrome in an infant from ingestion of Spirostachys africana complicated by measles co-infection. S. Afr. J. Child Health, 4(4): 112-113.
2. Bepe, N., Madanhi, N., Mudzviti, T., Gavi, S., Maponga, C.C. and Morse, G.D. (2011). The impact of herbal remedies on adverse effects and quality of life in HIV-infected individuals on antiretroviral therapy. J. Infect. Dev., Ctries. 5(1):48.
3. Bort, R., Macé, K., Boobis, A., Gómez-Lechón, M.J., Pfeifer, A. and Castell, J. (1999). Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. Biochem. Pharmacol., 58: 787-796.
4. Brosen K., Skjelbo, E., Rasmussen, B.B., Poulsen, H.E. and Loft, S. (1993). Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol.,. 45: 1211-1214.
5. Bungu, L., Frost, C.L., Brauns, S.C. and van de Venter, M. (2006). Tulbaghia violacea inhibits growth and induces apoptosis in cancer cells in vitro. Afr. J. Biotechnol., 5(20): 1936-1943.
6. Buwa, L.V. and van Staden, J. (2006). Antibacterial and antifungal activity of traditional medicinal plants used against venereal diseases in South Africa. J. Ethnopharmacol., 103: 139-142.
7. Canter, P.H. and Ernst, E. (2004). Herbal supplement use by persons aged over 50 years in Britain. Drugs & Aging, 21(9): 597-605.
8. Coller, J.K., Somogyi, A.A. and Bochner, F. (1999). Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms. Br. J. Clin. Pharmacol., 48: 158-167.
9. Delgoda, R., Younger, N., Barrett, C., Braithwaite, J. and Davis, D. (2010). The prevalence of herbs use in conjunction with conventional medicines in Jamaica. Complement. Ther. Med., 18(1): 13-20.
10. Draper, A.J., Madan, A., Smith, K. and Parkinson, A. (1998). Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes. Drug Metab. Dispos., 26: 299-304.
11. Duncan, A.C., Jager, A.K. and van Staden, J. (1999). Screening of Zulu medicinal plants for angiotensin converting enzyme (ACE) inhibitors. J. Ethnopharmacol., 68: 63–70.
12. Duri, Z.J., Hughes, N.A. and Munkombwe, N.M. (1992). Diterpenoids from Spirostachys africana. Phytochemistry, 31(2): 699-702.
13. Faber, M.S., Jetter, A. and Fuhr, U. (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin. Pharmacol. Toxicol., 97: 125–134.
14. Fasinu, P.S., Bouic, P.J. and Rosenkranz, B. (2012). An overview of the evidence and mechanisms of herb–drug interactions. Front. Pharmacol., 2012;3.
15. Fasinu, P.S., Gutmann, H., Schiller, H., Bouic, P.J. and Rosenkranz, B. (2013). The potential of Hypoxis hemerocallidea for herb-drug interaction. Pharm. Biol., 51(12): 1499-1507.
16. Fasinu, P.S., Gutmann, H., Schiller, H., James, A.D., Bouic, P.J. and Rosenkranz, B. (2013). The Potential of Sutherlandia frutescens for Herb-Drug Interaction. Drug Metab. Dispos., 41(2): 488-497.
17. Ferguson, C.S. and Tyndale, R.F. (2011). Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol. Sci., 32: 708-714.
18. Fugh-Berman, A. (2000). Herb-drug interactions. Lancet. 355: 134-138.
19. Galetin, A., Hinton, L.K., Burt, H., Obach, R.S. and Houston, J.B. (2007). Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr. Drug. Metab., 8(7): 685-693.
20. Gelfand, M., Mavi, S., Drummond, R.B. and Ndemera, B. (1985). The traditional medical practitioner in Zimbabwe. Mambo Press, Gweru, Zimbabwe.
21. Gerbal-Chaloin, S., Pascussi, J.M., Pichard-Garcia, L., Daujat, M., Waechter, F., Fabre, J.M., Carrère, N. and Maurel, P. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos., 29(3): 242-51.
22. Jurg, A., Tomás, T. and Pividal, J. (1991). Antimalarial activity of some plant remedies in use in Marracuene, southern Mozambique. J. Ethnopharmacol., 33(1-2): 79-83.
23. Kenworthy, K.E., Clarke, S.E., Andrews, J. and Houston, J.B. (2001). Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab. Dispos., 29: 1644-651.
24. Konecný, J., Jurica, J., Tomandl, J. and Glatz, Z. (2007). Study of recombinant cytochrome P450 2C9 activity with diclofenac by MEKC. Electrophoresis, 28(8): 1229-1234.
25. Kubeca, R., Velisek, J. and Musah, R.A. (2002). The amino acid precursors and odor formation in society garlic (Tulbaghia violacea Harv.). Phytochemistry, 60: 21-25.
26. Martignoni, M., Groothuis, G.M. and de Kanter, R. (2006). Species differences between mouse, rat, dog, monkey and human CYPmediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol., 2(6): 875-894.
27. Mathabe, M.C., Hussein, A.A., Nikolova, R.V., Basson, A.E., Meyer, J.J. and Lall, N. (2008). Antibacterial activities and cytotoxicity of terpenoids isolated from Spirostachys africana. J. Ethnopharmacol., 116(1): 194-197.
28. Mathabe, M.C., Nikolova, R.V., Lall, N. and Nyazema, N.Z. (2006). Antibacterial activities of medicinal plants used for the treatment of diarrhoea in Limpopo Province, South Africa. J. Ethnopharmacol., 105(1-2): 286-293.
29. McGaw, L.J., Jager, A.K. and Van Staden, J. (2000). Antibacterial, anthelmintic and anti-amoebic activity in South African medicinal plants. J. Ethnopharmacol., 72: 247-263.
30. Motsei, M.L., Lindsey, K.L., Van Staden, J. and Jager, A.K. (2003). Screening of traditionally used South African plants for antifungal activity against Candida albicans. J. Ethnopharmacol., 86: 235-241.
31. Munkombwe, N.M., Hughes, N.A. and Duri, Z.J. (1998). Acid metabolites from Spirostachys africana. Phytochemistry., 47: 1653-1655.
32. Munkombwe, N.M., Matswabi, T. and Hughes, N.A. (1997). Diosphenols from Spirostachys africana. Phytochemistry, 45: 1217-1220
33. Nowack, R. (2008). Review Article: Cytochrome P450 enzyme, and transport protein mediated herb–drug interactions in renal transplant patients: Grapefruit juice, St John's Wort–and beyond! (Review Article). Nephrology, 13(4): 337-347.
34. Ozkan, G., Baydar, H. and Erbas, S. (2010). The influence of harvest time on essential oil composition, phenolic constituents and antioxidant properties of Turkish oregano (Origanum onites L.). J. Sci. Food Agric., 90(2): 205-209.
35. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E. and Zeldin, D.C. (2006). The human intestinal cytochrome P450 ‘pie’. Drug Metab. Dispos. 34: 880-886.
36. Rendic, S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev., 34: 83-448.
37. Rettie, A.E. and Jones, J.P. (2005). Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol., 45: 477-494.
38. Rodrigues, A.D., Surber, B.W., Yao, Y., Wong, S.L. and Roberts, E.M. (1997). [O-ethyl 14C]phenacetin O-deethylase activity in human liver microsomes. Drug Metab. Dispos., 25: 1097-1100.
39. Schmider, J., Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., Duan, S.X., Karsov, D. and Shader, R.I. (1996). Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52: 125-134.
40. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423.
41. Singh, D., Kashyap, A., Pandey, R.V. and Saini, K.S. (2011). Novel advances in cytochrome P450 research. Drug Discov. Today, 16: 793-799.
42. Steenkamp, V. (2003). Traditional herbal remedies used by South African women for gynaecological complaints. J. Ethnopharmacol., 86: 97-108.
43. Tai, G., Dickmann, L.J., Matovic, N., DeVoss, J.J., Gillam, E.M. and Rettie, A.E. (2008). Re-engineering of CYP2C9 to probe acidbase substrate selectivity. Drug Metab. Dispos., 36(10): 1992-1997.
44. Tassaneeyakul, W., Birkett, D.J., Veronese, M.E., McManus, M.E., Tukey, R.H., Quattrochi, L.C., Gelboin, H.V. and Miners, J.O. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 265: 401-407.
45. Thamburan, S., Klaasen, J., Mabusela, W.T., Cannon, J.F., Folk, W. and Johnson, Q. (2006). Tulbaghia alliacea Phytotherapy: A Potential Anti-infective Remedy for Candidiasis. Phytother. Res., 20: 844-850.
46. Transon, C., Lecoeur, S., Leemann, T., Beaune, P. and Dayer, P. (2006). Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur. J. Clin. Pharmacol., 51: 79-85.
47. Ufer, M., Dilger, K., Leschhorn, L., Daufresne, L., Mosyagin, I., Rosenstiel, P., Haesler, R., Kuehbacher, T., Nikolaus, S., Schreiber, S. and Cascorbi, I. (2008). Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression. Clin. Pharmacol. Ther., 84(1): 43-46.
48. van den Heever, E., Allemann, J. and Pretorius, J. (2008). Influence of nitrogen fertilizers on yield and antifungal bioactivity of Tulbaghia violacea L. Hum. Exp. Toxicol. 27(11): 851-857.
49. van Vuuren, S.F., and Naidoo, D. (2010). An antimicrobial investigation of plants used traditionally in southern Africa to treat sexually transmitted infections. J. Ethnopharmacol., 130: 552-558.
50. Venkatakrishnan, K., von Moltke, L.L., and Greenblatt, D.J. (1998a). Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of high affinity component as an index of CYP1A2 activity. J. Pharm. Sci., 87: 1502-1507.
51. Venkatakrishnan, K., von Moltke, L.L. and Greenblatt, D.J. (1998b). Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J. Pharm. Sci., 87: 845-853.